aTYR PHARMA (ATYR) Research & Development (2014 - 2026)

aTYR PHARMA (ATYR) has reported Research & Development for 13 consecutive years, with $6.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 56.14% year-over-year to $6.7 million; the trailing twelve-month figure through Jun 2026 stood at $47.1 million (down 13.18% YoY), and the FY2025 full-year result was $60.2 million, up 10.75% from the prior year.
• Research & Development fell to $6.7 million in Q2 2026 per ATYR's latest filing, from $7.3 million in the prior quarter.
• Across five years, Research & Development topped out at $22.1 million in Q3 2025 and bottomed at $6.7 million in Q2 2026.
• Historically, Research & Development has averaged $11.9 million across 5 years, with a median of $11.4 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Research & Development jumped 150.38% in 2022, then tumbled 56.14% in 2026.
• Over 5 years, Research & Development stood at $14.9 million in 2022, then slipped by 14.45% to $12.8 million in 2023, then decreased by 4.13% to $12.2 million in 2024, then declined by 10.93% to $10.9 million in 2025, then slumped by 38.04% to $6.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $6.7 million, $7.3 million, and $10.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.